Harmony Biosciences Q2 revenue $261.3M (+30% YoY); EPS $1.28; reiterates FY guidance $1.0-1.04B

Harmony Biosciences Holdings, Inc.

Q2 net revenue $261.3M, up 30% YoY; average patients 8,950 (+450).
Net income $75.4M ($1.28 diluted EPS) vs $39.8M ($0.68) in Q2 2025.
Reiterates 2026 WAKIX net revenue guidance of $1.0B-$1.04B.
BP-205 Phase 1 SAD data favorable; Phase 1b in sleep-deprived volunteers starts Q3; Phase 2 mid-2027.
Cash and investments $962.5M as of June 30, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.